PubMed · 2873384
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1986-07-12. Precocious puberty.. https://pubmed.ncbi.nlm.nih.gov/2873384/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The Royal Tomb II was discovered in Vergina, Greece, in 1977. It contained a male skeleton and a rich array of grave goods. Evidence of trauma supposedly in the orbital bones of the skull has been thought to correspond to an eye injury that King Philip II is historically known to have suffered. However, reexamination of the orbital morphology showed no evidence of such pathology. Therefore, the skeleton does not belong to Philip II. New skeletal evidence shows that the skeleton belongs to King Philip III Arrhidaeus. In this case, the tomb may well contain some of the paraphernalia of Alexander the Great.
BACKGROUND: Multiple serum tests were performed on archival samples from patients who participated in trials to assess the ProstaScint scan staging ability. Traditional statistical analysis as well as artificial neural network (ANN) analysis were employed to evaluate individual patients and the group as a whole. The results were evaluated so that each factor was tested for prognostic value. METHODS: Data obtained from serum tests, bone scans, and ProstaScint scans were evaluated by traditional statistical methods and ANN to determine the individual value in clinical staging of prostate cancer. RESULTS: Two hundred seventy-five patients (180 postprostatectomy, 95 intact prostate) with prostate cancer (14 with distant metastases) were available for analysis. Data available included: clinical state (remission or progression), most recent clinical TNM stage, bone scan, and ProstaScint scan. Serum was tested for prostate-specific membrane antigen(PSMA), prostate-specific antigen(PSA), free PSA (fPSA), and complexed PSA (cPSA). Additional calculations included percent free PSA, and percent complexed PSA. Spearman individual statistical assessment for traditional group evaluation revealed no significant factors for T-stage. The free PSA and complex PSA had a significant association with node (N)-status. The distant metastases (M) stage correlated well with the bone scan and clinical stage. ANN analysis revealed no significant T-stage factors. N-stage factors showed a 95% sensitivity and 49% specificity. These factors included the presence or absence of a prostate, PSA serum levels, bone scan, and ProstaScint scans as major associated indicators. ANN analysis of the important variables for M-stage included ProstaScint scan score, and PSA levels (total, percent complexed, percent free, and fPSA). These factors were associated with a 95% sensitivity and 15% specificity level. CONCLUSIONS: Two hundred seventy-five patients receiving treatment for prostate cancer were evaluated by ANN and traditional statistical analysis for factors related to stage of disease. ANN revealed that PSA levels, determined by a variety of ways, ProstaScint scan, and bone scan, were significant variables that had prognostic value in determining the likelihood of nodal disease, or distant disease in prostate cancer patients.
Basic fuchsin labels microcracks, but a series of stains is required to differentiate between preexisting and test-induced microcracks and to label their growth in vitro. Basic fuchsin and five chelating agents-alizarin complexone, calcein, calcein blue, oxytetracycline, and xylenol orange-were randomly assigned to label microcracks in sequential rib sections from 10 donors. The density, length, and location of the microcracks did not differ significantly between the six stains, suggesting that each was equally effective in detecting microcracks. Paired specimens of trabecular bone were machined from bovine tibiae, stained with oxytetracycline, and fatigued in compression. One specimen from each pair was then stained with xylenol orange. Preexisting microdamage was stained with oxytetracycline, propagating microcracks with both stains and new, test-initiated damage with xylenol orange. Chelating agents are site-specific markers of the initiation and growth of microcracks.